Wyeth achieved positive preliminary results from a Phase I trial of a new oral formulation of methylnaltrexone, an investigational drug being developed with Progenics for the treatment of opioid-induced constipation (OIC). The latest data showed that a substantial majority of patients receiving the higher of the two doses tested, responded to treatment. The Phase I trial, conducted by Wyeth, was a double-blind, randomized, single-dose, crossover pharmacokinetic/pharmacodynamic study in subj...